The present disclosure relates generally to a system and method of providing radiation imaging and/or treatment, and more particularly to systems and methods for tracking of tumors during for projection image tracking of tumors during radiotherapy.
A Radiation therapy is widely used to identify and treat tumors in a patient. In radiation therapy, a high energy collimated beam of ionizing radiation is used to target tumorous tissue in the patient. The ionizing radiation damages the DNA of tissue in the tumor leading to cellular death and destroying the tumor. It will be understood that both the dose and placement of the ionizing radiation must be accurately controlled to ensure that the tumor receives sufficient radiation to destroy tumor tissue while damage to the surrounding healthy tissue is minimized. This can be problematic as in many therapies using conventional radiation therapy systems, since the patient's anatomy will often shift or move during the treatment, for example breathing induced movement. This movement can significantly reduce the accuracy and effectiveness of the radiotherapy treatment, particularly for therapies such as hypofractionated stereotactic body radiotherapy (SBRT) in which a highly collimated beam is used to deliver a high biological dose of radiation directly to the tumor.
Generally, there are two approaches for ensuring that the tumor receives sufficient radiation to destroy tumor tissue while damage to the surrounding healthy tissue is minimized. The first uses radiation-absorbing internal or external markers on the object (e.g., patient) on an initial or set-up scan, which a radiation therapist can use set the collimated beam of ionizing radiation relative to the markers. While useful for initial set-up, this approach has little utility in maintaining the collimated beam on the targeted tumor when the tumor moves unseen inside the patient.
A second approach uses megavoltage (MV) computed tomography (CT) imaging device. In this approach, the imaging device, commonly referred to as an MV electronic portal imaging device (EPID), is incorporated within the therapeutic radiation system, providing a beams-eye-view (BEV) of the tumor and the area being irradiated. This approach is attractive because it can be used to generate images of the tumor and surrounding soft-tissue immediately before, during or immediately following administration of a therapeutic dose of ionizing radiation. Moreover, an MV EPID can typically be implemented or retrofitted to a therapeutic radiation system without major changes to a linear accelerator of system used to generate the collimated beam of ionizing radiation.
In principle, an MV EPID can generate high contrast images of a tumor and surrounding soft-tissue contrast without the use of markers. However, in practice prior art EPID images exhibit low contrast. In one study, detailed in A. Richter et al., Feasibility Study for Markerless Tracking of Lung Tumors in Stereotactic Body Radiotherapy, International Journal of Radiation Oncology, Biology, and Physics, Vol. 78, no. 2, 2010, pp. 618-627, the EPID images were only clear enough to track less than about 47% of the tumors of the 40 patients in their study.
Hence there is a need for an improved system and method for projection image tracking of tumors during radiotherapy.
A system and method are provided for imaging and treatment of tumorous tissue in a patient.
In a first aspect, the invention is directed to a system including a radiation source for generating a radiation beam comprising high-energy photons for both high contrast imaging with lower photon energy distributions and efficient treatment of tumorous tissue with higher photon energy distributions, in a patient. The radiation source includes a charged particle accelerator that generates charged particles having energies of less than 6 megavolts (MV), a target of low Z to receive the charged particles and generate the high-energy photons of the radiation beam, and a collimator to emit the radiation beam. The system further includes an imaging device of high detective quantum efficiency (DQE) to define a target region of the tumorous tissue in the patient using the radiation beam, and a controller to determine a location and modulate the dose distribution for treatment of the tumorous tissue based on the defined target region, and to control the collimator to deliver radiation to the target region using the radiation beam.
In another aspect, the invention is directed to a method of treating a patient using such a system. Generally, the method includes: generating charged particles having energies of less than 6 megavolts (MV); applying the charged particles to a target of low Z<74 to generate a radiation beam comprising high-energy photons emitted by the target; defining a target region of tumorous tissue in the patient using the radiation beam and an imaging device with a high DQE(0)>0.04; determining a location and dose for treatment of the tumorous tissue based on the defined target region; and controlling the radiation beam to deliver radiation to the target region.
Embodiments of the present invention will be understood more fully from the detailed description that follows and from the accompanying drawings and the appended claims provided below, where:
The present disclosure is directed generally to projection image tracking of tumors during radiotherapy, and more particularly to a system and method for imaging and treatment of tumorous tissue in a patient.
The best cancer treatment delivery is obtained at MV (megavoltage) energies. It is possible to also image at MV energies and this can provide a tremendous targeting advantage because one can simultaneous see where the treatment dose is being delivered while the treatment process is in progress. The great advantage this gives is the opportunity to modulate in real time, the shape and dose distribution (across the shape) for maximum treatment dose delivery effectiveness to the cancer lesion while sparing surrounding healthy tissue from the strongly damaging effects of the radiation. This surrounding dose damage issue is a major and poorly solved problem currently in the field of radiation therapy.
Disclosed herein is a system and method that combines a reduction in MV energy of the treatment beam (e.g. from 4 to 6 MV), a lowering of the atomic number (Z) of a target material from that of the typically used tungsten (Z=74) to a material with a substantially lower Z, and use of an imager having a high detective quantum efficiency (DQE). In particular it is noted that the reduction in MV energy and lowering of the atomic number (Z) provide a larger fraction of the X-ray photons with energies down in the kV range, which provides better image contrast while still maintaining enough MV photons for good treatment delivery.
In the following description, numerous specific details are set forth, such as specific configurations, compositions, and processes, etc., in order to provide a thorough understanding of the present invention. In other instances, well-known systems and methods in the field of radiotherapy have not been described in particular detail in order to not unnecessarily obscure the present invention. Furthermore, it is to be understood that the various embodiments shown in the Figures are illustrative representations and are not necessarily drawn to scale.
An embodiment of a therapeutic radiation system including a megavoltage (MV) electron beam target, a computed tomography (CT) electronic portal imaging device (EPID), and method of using the same to and treat tumorous tissue in a patient will now be described in detail with reference to
A radiation source for generating a therapeutic radiation beam for both imaging and treatment of tumorous tissue in a patient will now be described in detail with reference to
Referring to
In accordance with embodiments of the present invention the x-ray target 208 is or includes a material having a low atomic number (Z). By a low atomic number it is a meant a material having a Z number less than that of Tungsten, Z=74, which is commonly used in such applications. The use of an x-ray target 208 having a lower Z number provides higher contrast than conventional MV electronic portal imaging devices (EPID) which allows better beams-eye-view (BEV) tracking of tumor motion during stereotactic body radiotherapy (SBRT). Lowering Z increase the distribution of lower energy photons that provide high contrast while still maintaining a good distribution of higher energy photons needed for efficient treatment dose delivery. Moreover, the higher contrast enables superior tracking.
In one embodiment, the x-ray target 208 is or includes a metal, such as an Aluminum plate (Z=13) having a thickness of between about 0.1 and about 10 cm, and more preferably a thickness of between about 0.3 and about 3 cm. In another embodiment, the x-ray target 208 is or includes a Beryllium plate (Z=4) having a thickness of between about 0.1 and about 10 cm.
In another embodiment, the x-ray target 208 is or includes a non-metal material having a having a low atomic number (Z). For example, in one embodiment the x-ray target 208 is or includes a carbon plate (Z=12) having a thickness of between about 0.4 and about 6 cm.
As discussed previously, the imaging device includes an imager that generates image signal/data in response to radiation incident thereon. Referring to
Referring to
Thus, embodiments of MV systems and methods for imaging and treatment of tumorous tissue in a patient have been described. In particular it is noted that the system and method of the present invention provides better image contrast while still maintaining enough MV photons for good treatment delivery combines a reduction in MV energy of the treatment beam (e.g. less than about 6 MV), a lowering of the atomic number (Z) of a target material from that of the typically used tungsten (Z=74) to a material with a Z of 13 or less, with the use of a high DQE imager (DQE(0)>0.04) to provide better image contrast while still maintaining sufficient MV photons for good treatment delivery.
Although the present disclosure has been described with reference to specific exemplary embodiments, it will be evident that various modifications and changes may be made to these embodiments without departing from the broader spirit and scope of the disclosure. Accordingly, the specification and drawings are to be regarded in an illustrative rather than a restrictive sense.
The Abstract of the Disclosure is provided to comply with 37 C.F.R. §1.72(b), requiring an abstract that will allow the reader to quickly ascertain the nature of one or more embodiments of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims. In addition, in the foregoing Detailed Description, it can be seen that various features are grouped together in a single embodiment for the purpose of streamlining the disclosure. This method of disclosure is not to be interpreted as reflecting an intention that the claimed embodiments require more features than are expressly recited in each claim. Rather, as the following claims reflect, inventive subject matter lies in less than all features of a single disclosed embodiment. Thus, the following claims are hereby incorporated into the Detailed Description, with each claim standing on its own as a separate embodiment.
Reference in the description to one embodiment or an embodiment means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment of the circuit or method. The appearances of the phrase one embodiment in various places in the specification do not necessarily all refer to the same embodiment.
Number | Name | Date | Kind |
---|---|---|---|
5138167 | Barnes | Aug 1992 | A |
5619042 | Hughes | Apr 1997 | A |
5754622 | Hughes | May 1998 | A |
6097787 | Siochi | Aug 2000 | A |
6208712 | Hernandez-Guerra | Mar 2001 | B1 |
6260999 | Wofford | Jul 2001 | B1 |
6272207 | Tang | Aug 2001 | B1 |
6353655 | Siochi | Mar 2002 | B1 |
6366641 | Whitham | Apr 2002 | B1 |
6445766 | Whitham | Sep 2002 | B1 |
6459762 | Wong | Oct 2002 | B1 |
6465957 | Whitham | Oct 2002 | B1 |
6477229 | Grosser | Nov 2002 | B1 |
6487274 | Bertsche | Nov 2002 | B2 |
6493424 | Whitham | Dec 2002 | B2 |
6519316 | Collins | Feb 2003 | B1 |
6535574 | Collins | Mar 2003 | B1 |
6727503 | Gerstenmayer | Apr 2004 | B1 |
6842502 | Jaffray | Jan 2005 | B2 |
6878944 | Gerstenmayer | Apr 2005 | B1 |
7030386 | Pang | Apr 2006 | B2 |
7085347 | Mihara | Aug 2006 | B2 |
7188999 | Mihara | Mar 2007 | B2 |
7239684 | Hara | Jul 2007 | B2 |
7397044 | Calderon | Jul 2008 | B2 |
7668292 | Bose | Feb 2010 | B1 |
7671342 | Bani-Hashemi | Mar 2010 | B2 |
7804936 | Pouliot | Sep 2010 | B2 |
7884438 | Partain et al. | Feb 2011 | B2 |
7945021 | Shapiro | May 2011 | B2 |
8284898 | Ho | Oct 2012 | B2 |
8355482 | Brown | Jan 2013 | B2 |
8440978 | Morf | May 2013 | B2 |
8483803 | Partain et al. | Jul 2013 | B2 |
8565377 | Robar | Oct 2013 | B2 |
8633445 | Star-Lack | Jan 2014 | B2 |
8658960 | Partain et al. | Feb 2014 | B2 |
8774351 | Funk | Jul 2014 | B2 |
20060262898 | Partain et al. | Nov 2006 | A1 |
Entry |
---|
A. Richter et al., Feasibility Study for Markerless Tracking of Lung Tumors in Stereotactic Body Radiotherapy, International Journal of Radiation Oncology, Biology, and Physics, vol. 78, No. 2, 2010, pp. 618-627. |
J. Seppi et al., Megavoltage Cone-Beam Computed Tomography Using a High-Efficiency Image Receptor, International Journal of Radiation Oncology, Biology, and Physics, vol. 55, No. 3, 2003, pp. 793-803. |
J. Rottmann et al.,Real-time soft tissue motion estimation for lung tumors during radiotherapy delivery, International Journal of Medical Physics Research and Practice, vol. 40, No. 9, Sep. 2013, pp. 1-7. |
J. Robara et al., Megavoltage Planar and Cone-Beam Imaging With Low-Z Targets: Dependence of Image Quality Improvement on Beam Energy and Patient Separation, International Journal of Medical Physics Research and Practice, vol. 36, No. 9, Sep. 2009, pp. 3955-3963. |
D. Roberts, et al., Comparative Study of a Low-Z Cone-Beam Computed Tomography System, Institute of Physics and Engineering in Medicine, vol. 56, 2011, pp. 4453-4464. |